Skip to main content

Advertisement

Table 1 Clinicopathological characteristics of lung cancer patients with compound EGFR mutations

From: First-generation EGFR tyrosine kinase inhibitor therapy in 106 patients with compound EGFR-mutated lung cancer: a single institution’s clinical practice experience

Variable Single common mutation (n = 115) Compound mutations (n = 106) P Double common mutations (n = 5) P Common + rare mutations (n = 11) P Rare + rare mutations (n = 13) P Rare + T790M mutations (n = 8) P Common + T790M mutations (n = 69) P
Sex
 Female 56 55 0.635 1 0.368 6 0.711 6 0.862 4 0.943 38 0.402
 Male 59 51 4 5 7 4 31
Age (years)
 < 60 57 63 0.141 2 0.675 5 0.794 8 0.413 7 0.063 41 0.195
 ≥ 60 58 43 3 6 5 1 28
Smoking status 0.270   0.118   0.795   0.442   0.795   0.022
 Non-smoker 69 69 1 5 4 5 54
 Smoker 34 24 3 3 4 3 11
 Unknown 12 13 1 0 5 0 4
Tumour status 0.034   0.592   0.782   0.753   0.103   0.064
 Recurrence 36 20 1 3 3 0 13
 Initial IIIb–IV 79 86 4 8 10 8 56
ECOG PS
 0–1 107 96 0.501 4 0.327 9 0.212 13 0.326 6 0.071 64 0.941
 2–4 8 10 1 2 0 2 5
Pathology 0.529   0.141   0.672   0.899   0.948   0.534
 ADC 110 102 4 10 13 8 67
 SCC 5 2 0 1 0 0 1
 LELC 0 1 1 0 0 0 0
 ASC 0 1 0 0 0 0 1
Timing of TKI 0.720   0.914   0.835   0.803   0.805   0.460
 First line 52 55 2 5 6 3 39
 Second line 55 46 3 6 7 5 25
 Third line 7 4 0 0 0 0 4
 Fourth line 1 1 0 0 0 0 1
TKI selection 0.034   0.981   0.592   0.214   0.161   0.021
 Gefitinib 64 47 3 5 4 2 33
 Erlotinib 26 41 1 4 4 4 28
 Icotinib 25 18 1 2 5 2 8
Response to TKIs
 PD 10 14 0.088 1 0.148 2 0.652 2 0.328 4 0.012 5 0.293
 SD 21 33 1 3 5 1 22
 PR 77 54 3 5 5 3 39
 CR 1 0 0 0 0 0 0
 NE 6 5 0 1 1 0 3
  1. ECOG PS Eastern Cooperative Oncology Group performance status, ADC adenocarcinoma, SCC squamous cell carcinoma, LELC lymphoepithelioma-like carcinoma, ASC adenosquamous carcinoma, PD progressive disease, SD stable disease, PR partial response, CR complete response, NE not evaluated, TKI tyrosine kinase inhibitor, PFS progression-free survival, OS overall survival
  2. All variables of different subgroups were compared with the single common mutation group; P < 0.05 was defined as significantly different